In 2022, Pfizer became the first biopharma company to generate annual revenue of $100 billion. | Led by cancer standout ...
As IntraBio works to grow the global treatment market for Aqneursa in Niemann-Pick disease type C, the company is already ...
Meanwhile, during the WSJ event in Davos this week, Pfizer’s Bourla also took aim at the Trump administration’s moves to cut ...
With star checkpoint inhibitors like Keytruda and Opdivo now sporting subcutaneous formulations, GSK has struck a deal aimed ...
After a series of headcount reductions in recent years, Takeda has disclosed a new round of cuts expected to affect ...
The “Rerouting Minds” webpage comprises information about LSD’s clinical history dating back to the 1930s, about how ...
The U.S. Supreme Court has decided to hear a case between Amarin Pharma and generic drugmaker Hikma that puts so-called ...
Curia Global is laying off 81 employees as part of its plan to shut down its drug product development and manufacturing ...
The New York powerhouse has agreed to surrender its 11.7% interest in the HIV-focused company for $1.875 billion. Under terms ...
Amid a viral social media trend glorifying the halcyon days of 2016, Novo Nordisk has gone back an extra decade to find ...
As the U.S. government intensifies efforts to acquire Greenland, President Donald Trump has responded to European pushback ...
With an FDA accelerated approval in November 2023, Ixchiq became the world’s first shot for chikungunya. Its retreat leaves Bavarian Nordic’s Vimkunya the only available chikungunya vaccine in the U.S ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback